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AbstrACt
Introduction Preference-based measures (PBMs) of 
health-related quality of life (HRQoL) are used to generate 
quality-adjusted life years, which are necessary for cost-
effectiveness evaluations of health interventions via cost–
utility analysis. These measures of health can be generic 
(ie, pandiagnostic) or condition speciic. No condition-
speciic PBM of HRQoL in Duchenne muscular dystrophy 
(DMD) exists, yet there are concerns that standard generic 
measures lack the speciicity to assess aspects of HRQoL 
that are especially important to people with DMD. This 
study has been designed to produce a condition-speciic 
PBM of HRQoL in DMD.
Methods and analysis This mixed-methods study 
proceeds through three stages. In the irst stage (concept 
elicitation), semistructured interviews will be conducted 
with boys and men diagnosed with DMD, and analysed 
with framework to produce a draft health state descriptive 
system for HRQoL in DMD. In the second stage (reining 
the descriptive system), patients, clinicians and primary 
caregivers of people with DMD will assess the face 
validity of the descriptive system. This will be followed 
by a quantitative survey on a larger sample of patients, 
which will be analysed with psychometric analyses to 
produce a reined descriptive system. In the third stage 
(valuation and econometric modelling), an online discrete 
choice experiment with duration will be administered to 
a general public sample to generate utility values for the 
new measure.
Ethics and dissemination This study has received ethical 
approval from the National Health Service (REC reference: 
18/SW/0055). The primary output of this research will 
be a condition-speciic PBM (or ‘bolt-on’ to an existing 
generic PBM) in people with DMD and an associated value 
set. Results will be disseminated through international 
conferences and open-access journals.
IntroduCtIon 
Duchenne muscular dystrophy (DMD) is 
an inherited neuromuscular disorder that 
predominantly affects boys and men. It has 
an estimated incidence of 1:3800 to 1:6300 
in live births.1 The disease causes progressive 
muscle weakness due to an absence of the 
dystrophin protein, which functions to help 
keep muscle cells intact. Diagnostic symptoms 
and functional impairment are evident from 
as early as 2 years old and average life expec-
tancy of people with DMD is approximately 
25 years,2 although increasingly people with 
DMD are surviving into their fourth and 
even fifth decades.3 4 The disease progresses 
through four recognised clinical stages char-
acterised by increased muscle weakness, 
impaired ambulation and motor functioning, 
and cardiovascular and respiratory prob-
lems.5 There is no known cure for the disease. 
Current clinical efforts are thus focused on 
improving the health-related quality of life 
(HRQoL) of people with DMD, which is 
considerably lower than that expected in a 
state of perfect health.4 Health interventions, 
therefore, are necessarily evaluated for their 
cost-effectiveness in improving HRQoL. The 
strengths and limitations of this study
 Ź This study will produce a systematic health state 
descriptive system for describing health-related 
quality of life (HRQoL) in people with Duchenne mus-
cular dystrophy (DMD) using complementary mixed 
methods.
 Ź The primary output of the study will be the irst con-
dition-speciic preference-based measure of HRQoL 
in people with DMD, which can be used in cost-ef-
fectiveness evaluations of new interventions.
 Ź The study features input from a multidisciplinary 
team working with the charity Duchenne UK, cli-
nicians, patients and primary caregivers of people 
with DMD.
 Ź Given the recruitment methods, there is likely to be 
some selection bias in the samples, and sample siz-
es in some parts of the study (quantitative patient 
surveys) will be acceptable but may be lower than 
optimal due to DMD being a rare disease.
 Ź The design and validity of the measure and accom-
panying value set are restricted to the UK, and will 
not be demonstrated internationally without further 
study.
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most common form of economic evaluation of health 
interventions is cost–utility analysis, which is used to 
compare interventions based on their cost per quality-ad-
justed life year (QALY).6 The QALY is a single measure 
that combines information on changes in both quantity of 
life and HRQoL, and is required by the National Institute 
for Health and Care Excellence (NICE) in the UK during 
health technology assessment.7 In order to derive a QALY, 
utilities (or preference weights) for different health states 
are required, which are often obtained from generic pref-
erence-based measures (PBMs) of health. PBMs of health 
have two components: a health state descriptive system 
that can be used to describe all possible different health 
states defined by a set of multilevel dimensions; and a set 
of utility weights (or value set) that represent the relative 
preferences people have for the different health states. 
Development of a PBM, thus, typically involves a mixed-
methods approach: involving qualitative and subsequent 
quantitative psychometric methods for the generation 
and validation of the descriptive system, and a valuation 
survey for the value set.6 
PBMs can either be generic, and designed for use across 
all health conditions, or condition specific. Previous PBMs 
used to assess HRQoL in DMD have been generic and 
have included the EuroQol-5-Dimensions (EQ-5D)8 9 and 
the Health Utilities Index (HUI).10 Generic measures are 
often recommended in the assessment of health technol-
ogies, as they allow for relative comparisons across health 
conditions. However, generic measures often lack the 
specificity to assess aspects of HRQoL that may be espe-
cially important to a particular health condition or group 
of health conditions. For example, neither the EQ-5D nor 
the HUI appears to adequately measure fatigue,11–14 social 
participation12 15–17 or dignity,14 18 19 which have been 
shown to be important aspects of HRQoL for people with 
DMD. The HUI has a greater number of dimensions (and 
thus greater coverage) than the EQ-5D, and some limited 
research suggests the HUI may outperform the EQ-5D 
in people with disabilities, such as on proxy reliability.20 
However, the demonstration of adequate measurement 
properties of these generic PBMs in people with neuro-
disability is lacking.21 Neither of these generic PBMs 
cover the full range of aspects of HRQoL that may be 
important to people with muscular dystrophies, including 
DMD.22 This is problematic, as they have been used to 
generate HRQoL utilities for economic evaluations in 
DMD.23 Quality of life measures that have been designed 
for use in people with DMD, such as the Quality of Life 
in Neuromuscular Disease instrument,24 are not prefer-
ence based and thus cannot be used to generate QALYs 
directly. Moreover, different measures may be used across 
different clinical stages of DMD and throughout the 
life course, making it difficult to compare estimates of 
HRQoL on a common index, which is desirable for users 
to inform health technology assessment.
This study has been designed to evaluate the content 
validity of three existing, well-used generic PBMs of 
HRQoL (the EQ-5D for adults or the EQ-5D-Y which 
is the youth version; the HUI, based on the HUI2 and 
HUI3 classification systems; and the Child Health Utility 
9D [CHU-9D]), while generating the content for a new 
condition-specific PBM, or condition-specific ‘bolt-on’ 
addition to an existing PBM, calibrated for assessing 
HRQoL in people with DMD. Bolt-ons are additional 
dimensions added onto an existing measure where 
there is a concern that the measure does not capture all 
important dimensions, but where the existing dimensions 
including severity levels are appropriate.25–27 As is typical 
in studies that involve the development of patient-re-
ported outcome measures,28 this research involves mixed 
methods and proceeds through three sequential stages.
In the first stage of concept elicitation, semistructured 
qualitative interviews will be conducted with boys and 
men diagnosed with DMD and analysed to produce a 
draft health state descriptive system for HRQoL in DMD. 
In the second stage of refining the descriptive system, the 
face validity and the psychometric properties of a ques-
tionnaire derived from the draft descriptive system will 
be assessed and improved using mixed methods, in order 
to produce a refined descriptive system and question-
naire for measuring HRQoL in DMD. In the third and 
final stage of valuation and econometric modelling, a 
discrete choice experiment with duration (DCE
TTO
) will 
be used in a survey of the general public, where they will 
be asked to value health states selected from the refined 
health state descriptive system in order to derive the value 
set. This protocol outlines the design and methodology, 
we will use in each of the three stages of the research 
(summarised in figure 1). The product will be a rigorous 
PBM or bolt-on(s) to an existing PBM, of HRQoL in 
people with DMD for use in the economic evaluation of 
health interventions.
This work is funded by the charity Duchenne UK and 
falls under the umbrella of ‘Project Hercules’ (Health 
Research Collaboration United in Leading Evidence 
Synthesis) led by the charity. It is designed to develop 
common tools and practices in health technology assess-
ment for DMD to improve engagement between industry 
and international agencies such as NICE on decisions on 
which medicines and treatments to fund. This includes 
a need for a robust and valid preference-based HRQoL 
metric to use to assess the cost-effectiveness of treatments.
AIMs
This study has the following three aims:
1. Using both bottom–up (qualitative) and top–down 
(review) methods generates a draft descriptive system 
for measuring HRQoL in people with DMD.
2. Using face validity and psychometric analyses with pa-
tients with DMD, and their primary carers and clini-
cians refine the initial draft descriptive system generat-
ed in (1) to produce a final, refined descriptive system, 
suitable for assessing HRQoL in DMD.
3. Design and conduct a valuation study using DCE
TTO
, 
with the adult UK general public to produce utility 
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values for all health states defined by the descriptive 
system generated in (2).
MEthods And AnAlysIs
stage 1: concept elicitation
Study design and procedure
Development of a topic guide
A topic guide or ‘interview schedule’ will be used to help 
provide structure to the semistructured qualitative inter-
views and ensure that all important a priori information 
on HRQoL in people with DMD is covered.29 The topic 
guide will be informed by a rapid scoping review of the 
literature on HRQoL themes in DMD,30 and the content 
of the generic PBMs of HRQoL assessed in this study 
(ie, the EQ-5D-Y/EQ-5D, HUI and CHU-9D). Experts 
through experience, including clinicians and caregivers 
to people with DMD, will be asked to informally review 
the topic guide to evaluate its face validity and inclusivity, 
prior to the interviews. These experts will be identified 
by Duchenne UK, as part of Project Hercules advisory 
groups. The selection of experts informing this project 
will be intended to generate a breadth of clinical exper-
tise, but will ultimately be determined by convenience 
sampling (ie, based on experts’ availability in accordance 
with the project timelines).
Qualitative interviews
Participants with a primary diagnosis of DMD will be 
sent an invitation to take part in a 60 min semistructured 
interview exploring the domains of their HRQoL. The 
semistructured topic guide ensures important topics of 
interest are covered, while allowing the flexibility for elab-
oration and follow-ups in the case of interesting or ambig-
uous points made by the interviewee.29 Across a number 
of areas, participants will be asked about their HRQoL 
and whether the EQ-5D-Y/EQ-5D, HUI or CHU-9D 
adequately captures this dimension. Participants will also 
be asked to provide details on any dimensions of HRQoL 
that are important to them but are not covered in the 
topic guide.
Participants will be sent a study pack directly by post 
from a recruiting National Health Service (NHS) site 
(see below), but will have to contact the research team 
should they wish to take part. The study pack will contain 
an invitation letter, information sheet, consent form, 
background details form and interview schedule. This 
content allows the participant to familiarise themselves 
with the material, and thus maximise the quality of subse-
quent interview data and informed consent of what is 
involved.31 Participants will also be given a template noti-
fication letter for their general practitioner (GP), which 
they can pass on if and when they decide to disclose their 
participation in the study to their GP.
One experienced qualitative researcher will conduct 
the interviews to ensure consistency throughout. To facil-
itate inclusivity, interviews will take place in the preferred 
location/medium and time for the participant. Interviews 
could thus take place face to face on NHS sites, Univer-
sity premises, participants’ homes and remotely via the 
telephone and Skype, where necessary (tools like Skype 
have been shown to be a valid alternative to face-to-face 
interviews in qualitative methods).32 While it is preferred 
that the interviews take place with the participants alone 
(to avoid biased responses), the presence of others, such 
as a caregiver, and/or parent(s) and guardian(s) in the 
case of children (under 16 years old), will be facilitated 
on the participant’s and/or consenting parent’s wishes. 
In all cases with children, the parent or guardian will be 
asked to remain in the vicinity of the interview (ie, in the 
same building). Participants or a parent/guardian in the 
case of children will give their informed consent prior 
to data collection, using a consent form. All interviews 
Figure 1 Research project process diagram. Design stages omitted. DCE, discrete choice experiment; DMD, Duchenne 
muscular dystrophy; HRA, Health Research Authority; HRQoL, health-related quality of life; IRT, Item response theory; QoL, 
quality of life. 
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will be digitally recorded on an encrypted device, tran-
scribed verbatim by the research team and anonymised. 
As well as taking part in an interview, participants will 
complete a brief background details form, indicating 
some broad clinical and background characteristics to 
ensure we interview a sufficiently broad cross-section 
of people with DMD. These background characteristics 
include brief questions on lower and upper limb mobility, 
ventilator use, use of steroid and heart medication, and 
age. All documents and the study methodology have been 
approved by the Duchenne UK Project Hercules advisory 
groups.
Producing a draft descriptive system
The qualitative data will be analysed to produce themes, 
used to populate a draft health state descriptive system of 
HRQoL in DMD. The draft descriptive system will be used 
to generate multiple HRQoL items as part of a question-
naire to be administered in a patient sample of people with 
DMD in stage 2. The draft descriptive system will be circu-
lated for expert comments and feedback from Duchenne 
UK via the Project Hercules advisory groups. As well as 
from participants themselves, by ‘member checking’, the 
results to make sure they are consistent with participants’ 
perspectives.33 This methodology has been previously 
applied by members of the research team to generate 
descriptive systems for PBMs in other health condi-
tions.34 35 Assuming, as predicted, that generic PBMs (ie, 
the EQ-5D-Y/EQ-5D, HUI and CHU-9D) are insufficient 
to capture all important domains uncovered by the qual-
itative research, the research project will progress onto 
stage 2. If, in the unlikely event that, the generic PBMs 
capture all important domains of HRQoL to people with 
DMD, then we would not continue with the latter stages 
of the research, and would instead inform all relevant 
parties, including the relevant research ethics committee 
and transparently report on our findings as they have 
emerged.
Study sample and recruitment
Participants for stage 1 will be identified by NHS health-
care teams across five collaborating sites in the UK that 
specialise in the care and treatment of children and/
or adults with DMD. The sites will identify and contact 
potential participants directly with a study pack (without 
any disclosure of patient data to the research team). 
Participants will then need to contact the research team 
if they are interested in taking part. Potential partici-
pants will be purposively sampled, in order to ensure a 
sufficient degree of representation across age, lower and 
upper limb function, and respiratory function, as advised 
by families of people with DMD via Duchenne UK. An 
illustrative sampling framework is shown in table 1. 
Recruitment will proceed in an iterative fashion, whereby 
these selection characteristics are monitored to ensure a 
good balance across them. Participants will be recruited 
to ensure coverage across the life course of people with 
DMD, from childhood to adulthood. A minimum age of 7 
years has been applied, based on previous work suggesting 
children at this age are capable of reporting on aspects of 
their HRQoL.36 The inclusion and exclusion criteria for 
each stage of the study are illustrated in table 2.
The sample size for the qualitative research interviews 
will be determined by data saturation. Data saturation is 
achieved when no additional novel themes are emerging 
from interviews with participants and a sufficient number 
of participants with different characteristics (as defined 
above) have been interviewed. While it is impossible to 
determine the exact number of participants required to 
reach data saturation in advance, prior studies of patients’ 
perspectives on HRQoL in different specific health condi-
tions provide an informed estimate of between 30 and 60 
people.34 35 Assuming a 50% uptake rate from potential 
participants, each site will be asked to identify between 12 
and 25 potential participants.
Data analysis plan
The interview transcripts in stage 1 will be subjected to 
thematic content analysis using framework, an approach 
developed in the context of applied policy research.37 
Briefly, framework is a form of thematic content analysis 
that involves coding and identifying common categories 
emerging from the data, which are indexed and then 
grouped into themes (or attributes). NVivo qualitative 
analysis software will be used to facilitate and manage the 
analysis. The trustworthiness (quality) of the qualitative 
analysis will be assured using the four criteria of trustwor-
thiness, which includes ‘member checking’.33 Stage 1 of 
the project is estimated to take approximately 12 months.
Table 1 An example sampling framework for a recruiting 
site, based on a maximum identiied sample of 25 potential 
participants
Clinical criteria
Lower limb 
function ᅚ x x x x
Gross upper limb 
function
ᅚ ᅚ ᅚ x x
Respiratory 
function
ᅚ ᅚ x ᅚ x
Age group Total
Preadolescence (<10 years) 2 2 0 0 0 4
Early adolescence (10–14 years) 2 2 1 1 0 6
Late adolescence (15–19 years) 0 2 2 2 1 7
Early adulthood (20–29 years) 0 0 1 2 2 5
Middle adulthood (30–39 years) 0 0 0 0 2 2
Late adulthood (>39 years) 0 0 0 0 1 1
‘Lower limb function’ is based on the ability to walk 
independently without a mobility device; ‘gross upper limb 
function’ is based on the ability to raise a hand to mouth to 
eat/drink independently; ‘respiratory function’ is based on 
the absence of any ventilation. Cell counts represent cross-
tabulations between clinical criteria and age group, and are 
approximations.
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stage 2: reining the descriptive system
Study design and procedure
Stage 2a: ensuring face validity
In stage 2a, a small sample of patients with DMD, primary 
caregivers of people with DMD and clinicians will be 
invited to assess the face validity of the draft descriptive 
system. They will be asked to complete a series of tasks 
to check that the questionnaire is suitable for adminis-
tration in a larger sample (ie, that it can be understood 
by all parties and makes sense, including the wording 
of instructions, items and response options). This exer-
cise will be completed in the presence of the researcher, 
and, to minimise participant burden, will be offered face 
to face or remotely (eg, via Skype or telephone) as in 
the interviews for stage 1. Participants (which includes 
patients who have taken part in stage 1; see below) will be 
sent an information sheet and consent form in advance 
to give them time to decide whether or not to take part 
in the study. Participants will provide consent in the same 
way as that in stage 1 (above), and the same procedural 
details will apply.
Following consent, participants will be asked to 
complete the draft questionnaire in the presence of the 
researcher (either physically or remotely) to check that 
they can fill it in accurately and understand it. Following 
this, participants will be asked to complete a ranking exer-
cise to determine the ordering of the response levels for 
the questionnaire, and a ‘cognitive debriefing’ exercise 
(where participants are asked what they think the items 
mean) to ensure that the items are measuring what they 
are intended to. If any patients have not provided back-
ground details as part of an interview in stage 1, this will 
also be included. In place of basic aggregate clinical back-
ground details, we will collect basic age (decade ranges) 
and gender information from clinicians and primary 
caregivers of people with DMD to provide basic descrip-
tive background on the sample. Participants will also be 
given a template notification letter for their GP which 
they can pass on if and when they decide to disclose their 
participation in the study to their GP. These methods 
have previously been used by members of the research 
team in developing condition-specific measures in other 
health conditions.35 38 This exercise will not be recorded, 
but anonymous notes will be taken by the researcher on 
potential modifications to the questionnaire to make it as 
fit-for-purpose and user-friendly as possible. In total, the 
face validity exercise is expected to take approximately 
30 min.
Stage 2b: quantitative surveying
In stage 2b, quality of life items derived from the descrip-
tive system developed in stage 1 (refined as necessary 
in stage 2a), and a selection of generic PBMs informed 
by the results of stage 1 to facilitate comparability (eg, 
the EQ-5D-Y/EQ-5D, HUI and/or the CHU-9D), will be 
administered to as wide as possible a patient sample of 
people with DMD. Participants with a diagnosis of DMD 
will be invited to complete a survey online, or offline by 
Table 2 Sample inclusion/exclusion criteria for the three study stages
Inclusion criteria Exclusion criteria
Stage 1 Boys and men diagnosed with DMD Women with DMD or those with other forms of muscular 
dystrophy
Aged 7+ years old Aged <7 years old
Fluent in English Unable to understand or speak English
Have the capacity to consent (or receive parental 
consent if <16 years old)
Lacking in the capacity to consent (or receive parental 
consent)
Stage 2a Same criteria as stage 1 for patients Same criteria as stage 1 for patients
Clinicians and caregivers of people with DMD, aged 
18+ years old, luent in English, possessing the capacity 
to consent.
People who are not clinicians or caregivers of people 
with DMD or clinicians and caregivers who do not meet 
the inclusion criteria.
Stage 2b Same criteria as stage 1 for patients Same criteria as stage 1 for patients
Proxy or assisted reporting by people aged 
18+ years old who have the appropriate authority to 
respond on behalf of a patient diagnosed with DMD, 
luent in English, possessing the capacity to consent.
People who are not providing proxy or assisted 
reporting for, or do not have the appropriate authority to 
respond on behalf of, patients diagnosed with DMD, or 
those who do who do not meet the inclusion criteria
Stage 3 Men and women from the UK general population People with a diagnosis of DMD or other forms of 
muscular dystrophy
Aged 18+ years old Aged <18 years old
Fluent in English Unable to understand or speak English
Have the capacity to consent Lacking in the capacity to consent
Additional iterative sampling strata apply to the qualitative interviews to ensure suficient breadth of coverage.
DMD, Duchenne muscular dystrophy. 
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request to the researchers for a paper copy. Potential 
participants will be sent a study pack directly by post from 
a recruiting NHS site (see below) or respond to adverts 
circulated by charities and support groups, coordinated 
by Duchenne UK. Participants will be required to read 
an information sheet and provide their informed consent 
(or the consent of a parent or guardian in the case of chil-
dren) prior to completing the survey. These documents 
will be enclosed with the invitation letter for participants 
and made compulsory reading on the survey website 
prior to accessing the study measures. While self-reported 
responses are desirable, to facilitate inclusivity we will 
make the survey as accessible as possible to assisted self-re-
port and proxy responders. Participants will be asked to 
note on the survey whether they are completing it them-
selves (self-report), with help from another (assisted 
self-report), or someone is completing it on their behalf 
(proxy). It is anticipated that the survey will take up to 
10 min of participants’ time.
Producing a reined health state descriptive system
The quantitative data from the surveys of people with 
DMD in stage 2b will be subjected to psychometric anal-
yses (see below), along with expert input from the Project 
Hercules advisory groups, to produce a final health state 
descriptive system.39 Depending on the results of stage 
1, stage 2 and expert input, this will either form a new 
HRQoL measure, or ‘bolt-on’ dimensions to an existing 
generic PBM, such as the EQ-5D-Y/EQ-5D, HUI or 
CHU-9D.
Study sample and recruitment
In stage 2a (face validity exercise), participants will be 
those patients that have taken part in stage 1 and have 
consented to be contacted for further research by the 
research team, and clinicians and primary caregivers of 
people with DMD identified by Duchenne UK via their 
advisory groups. This is a pilot activity designed to ensure 
the questionnaire is ‘fit-for-purpose’ prior to administra-
tion in a larger sample. A total sample size of 30 partici-
pants, composed of 10 clinicians, 10 primary caregivers of 
and 10 people with, DMD, based on similar previous face 
validity work.38 In the event that more than 10 people with 
DMD from stage 1 have agreed to be contacted for further 
research, participants will be selected to ensure breadth 
across the stage 1 sampling framework in (table 1).
In stage 2b (quantitative patient survey), participants 
will be those that have taken part in stage 1 and have 
consented to be contacted for further research by the 
research team; additional participants identified by the 
healthcare team; or additional participants identified via 
advertisements circulated by DMD charities and support 
groups (coordinated by Duchenne UK). The identifi-
cation of potential participants by the healthcare team 
will proceed in the same fashion as that in stage 1 (with 
study packs provided to potential participants in their 
care). The number which they identify will be as many 
as possible that meet the inclusion or exclusion criteria, 
but this will be preagreed with sites to align with capacity 
(with an optimal number of approximately 40 additional 
participants per site). While similar prior studies have 
used samples of approximately 342–655 patients,39 40 as 
DMD is a rare health problem, it is important to recognise 
that such numbers may be difficult to achieve in practice. 
Recent simulations have suggested that sample sizes of at 
least 100 people and above produce stable estimates in 
Rasch analyses,41 from which to draw conclusions, and so 
we have set this as our target minimum sample size, while 
aiming for an optimal sample of 300 people or greater.
Data analysis plan
In stage 2a, face validity will be assessed using ranking 
and debriefing exercises in a small sample of DMD 
patients, primary caregivers and clinicians. This will 
also involve taking anonymous notes of the responses 
and making refinements to the draft questionnaire as 
a result of feedback. Similar methods have been used 
to help develop condition-specific measures for ambly-
opia and self-management in diabetes.35 38 Refinement 
of the descriptive system in stage 2b will involve factor 
analysis, Rasch analysis and standard psychometric anal-
yses as used in previous work by members of this group, 
with the aim of producing a health state descriptive 
system appropriate for measuring the HRQoL of people 
with DMD.39 40 Factor analysis will be used to examine 
domains. Rasch and standard psychometric analyses will 
be used to examine differential item functioning across 
important subgroups (where feasible given the sample 
size), item response distributions, item severity, ability for 
items to discriminate by severity, whether item response 
options are ordered by severity and correlations between 
items. In the assessment of items, these analyses will be 
combined based on prior predefined criteria used in 
previous measure development by this research group.42 
Alongside all previous results and analyses in the study, 
this psychometric analysis will be used to ensure the best 
performing items remain in the final measure used for 
valuation in stage 3. Stage 2 of the project is estimated to 
take approximately 4 months.
stage 3: valuation and econometric modelling
Study design and procedure
Designing the DCE
An increasingly widely used preference elicitation tech-
nique for valuing health is the DCE
TTO
, which is a tech-
nique that can be conducted online and data can be 
modelled to generate utility values for all states defined 
by the descriptive system.43 44 The technique asks 
respondents to choose between two profiles, where each 
profile is described using a severity level of each of the 
dimensions from the descriptive system, plus a duration 
level (based on remaining life expectancy). Respon-
dents are asked to choose which profile they think is 
best. The duration attribute will be 1, 4, 7 and 10 years, 
as used in recent surveys.44 45 Profiles will be selected for 
inclusion in the DCE
TTO
 using a D-Optimal design using 
 o
n
 27 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023685 on 9 March 2019. Downloaded from 
7Powell PA, et al. BMJ Open 2019;9:e023685. doi:10.1136/bmjopen-2018-023685
Open access
the specialist software Ngene. Illogical combinations of 
the attributes will be identified and excluded from the 
design. The design will also select which profile appears 
as A or B, and the combinations of profiles that each 
respondent values. Based on the expected size of the 
descriptive system, 200 health profile combinations 
will be valued, and each respondent will undertake 
10 tasks, leading to 50 observations per health profile 
combination. In the DCE
TTO
, respondents will be asked 
to imagine the hypothetical health profiles for them-
selves, and asked which they think is best. They will not 
be told the underlying health condition (DMD) or that 
the profile is typically experienced by children, which 
causes problems regarding people’s willingness to sacri-
fice a reduction in life expectancy to improve the health 
of the child (which is the method the technique uses to 
generate utility values). This perspective has been taken 
in other child valuation surveys, including the UK valu-
ation of the CHU-9D,46 and the Netherlands valuation 
of the CHU-9D, which also used the DCE with duration 
technique conducted online.45
Conducting the DCE
In order to produce utility values for health states defined 
by the health state descriptive system, DCE
TTO
 will be used 
in an online survey of 1000 members of the UK adult 
general population. The adult general population was 
also used in the UK and Netherlands valuation of the 
CHU-9D, and is consistent with the NICE methods guide 
for valuation, where adult general population values are 
sought rather than patient values.7 Furthermore, the 
elicitation of child values presents a large number of 
challenges around whether they are cognitively able to 
undertake health state valuation tasks and little research 
has been undertaken on this.47 The survey will be hosted 
on Qualtrics, survey software supported at the host 
research institution. Participants will read an information 
sheet online and provide their informed consent online 
at the start of the survey. The survey will have three parts. 
First participants will complete questions about them-
selves and their health, second they will complete one 
practice question and 10 DCE
TTO
 questions, and finally, 
they will report what they thought of the survey. Partic-
ipants successfully completing the survey will receive a 
predetermined reward from the market research agency 
in line with the agencies usual procedure.
Valuation using the DCE
Health states will be valued using the DCE
TTO
 data derived 
from the online survey using standard regression tech-
niques (see below). This exercise will produce utility 
values for each (health state) attribute level defined by 
the condition-specific PBM of HRQoL in DMD, for use in 
cost-effectiveness evaluations of new interventions.
Study sample and recruitment
Identification and recruitment of the sample for stage 
3 will be outsourced to a reputable market research 
company that conforms to governance standards (eg, the 
Market Research Society Code of Conduct). Participants 
will be invited to take part in the survey through email or 
via a portal by the market research agency with a link to 
the online survey. This method of recruitment has been 
used successfully by members of the research team on 
previous health valuation projects.45 48 A predetermined 
sample size of 1000 people from the general population 
will be used. This sample size has been selected to ensure 
that each pair of health profiles is valued well in excess 
of a minimum of 20 times and a minimum of one pair of 
profiles per parameter estimated is selected in the regres-
sion model.49
Data analysis plan
The DCE
TTO
 surveys completed in stage 3 will be anal-
ysed by regression analysis to produce utility values for 
health states defined by the health state descriptive 
system.43 The utility value of each level of each attribute 
is generated using the ‘marginal rate of substitution’, 
generated by dividing the coefficient for each level of 
each attribute by the coefficient for duration, producing 
the utility value for each (health state) attribute level. 
Choices will be modelled using the conditional logistic 
model. Sensitivity analysis will be undertaken to assess 
the robustness of the results by excluding respondents. 
Similar methods have been used elsewhere by this 
group.45 48 Stage 3 of the project is estimated to take 
approximately 4 months.
Patient and public involvement
This research was driven by a recognised need within 
the Duchenne community to better measure quality of 
life in people with DMD. At the outset, their views were 
represented by the charity Duchenne UK, which includes 
mothers of sons with DMD. Duchenne UK, under the 
work stream of Project Hercules, has contributed to the 
design of the proposed project. There is an established 
patient and public involvement (PPI) group, which 
includes adults with DMD and parents of children with 
DMD. The group will contribute as research peers at 
several key stages of the project, including stage 1 and 
stage 2 during item generation and item selection. The 
research findings will be disseminated to participants 
via Duchenne UK, through established communication 
channels with members of the Duchenne community 
and a bespoke Project Hercules event scheduled for 
November 2019.
EthICs And dIssEMInAtIon
The work will be conducted in accordance with the 
ethical principles underlying the Declaration of Helsinki 
and good practice guidelines on the proper conduct 
of research. A full data management plan is in place to 
ensure the appropriate handling and use of personal and 
non-identifiable data, necessary for the successful conduct 
of this research. Advisory groups, in the form of steering 
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and PPI groups, are being set up by Duchenne UK as part 
of Project Hercules to help advise and oversee the find-
ings that emerge from the research, including advising 
on ethical and practical issues such as patient burden. All 
study documents and the study methodology have been 
approved by Duchenne UK and parents of patients with 
DMD.
The primary output of this research will be a condi-
tion-specific PBM (or bolt-on to an existing measure) 
for assessing HRQoL in people with DMD, and an asso-
ciated value set for use in cost-effectiveness evaluations. 
The results of this project will be disseminated via at 
least two international conferences and two journal 
manuscripts (ie, one for stages 1/2 and one for stage 
3). The manuscripts will be published open access to 
ensure the findings of the research are freely avail-
able, transparent and accessible to all with an interest 
in reading about them. Non-technical report(s) of the 
findings will also be circulated to study stakeholders via 
Duchenne UK.
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